NCT07109453

Brief Summary

To Check Dermatological Safety of Test Products by 24 Hours Patch Testing

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 31, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 7, 2025

Completed
18 days until next milestone

Study Start

First participant enrolled

August 25, 2025

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

August 8, 2025

Status Verified

July 1, 2025

Enrollment Period

7 days

First QC Date

July 31, 2025

Last Update Submit

August 7, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • To evaluate the dermatological safety of the test products by 24 Hours Patch

    Test Dermatological safety of the test products by 24 Hours Patch Test will be evaluated by 0: No reaction and 4 Severe Reaction

    Irritation Scoring at T30 minutes and 24 hours post patch removal. Scoring can be done at T168 hours post-patch removal if needed

Secondary Outcomes (1)

  • Safety of the skin

    At T30 minutes and 24 hours post patch removal. Scoring can be done at T168 hours post-patch removal if required

Study Arms (1)

18 Test Products along with Positive and Negative Control

EXPERIMENTAL

1. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.

Other: 18 Test Products along with positive and negative control

Interventions

1\. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.

18 Test Products along with Positive and Negative Control

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: 18-65 years (both inclusive) at the time of consent.
  • Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
  • Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale).
  • Females of childbearing potential must have a self-reported negative pregnancy test.
  • Subject who do not have any previous
  • history of adverse skin conditions and are not under any medication likely to interfere with the results.
  • Subject is in good general health as determined by
  • the Investigator on the basis of medical history.
  • Subjects is willing to maintain the test patches in designated positions for 24 Hours.
  • Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
  • Subject must be able to understand and provide written informed consent to participate in the study.
  • Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.
  • For Sensitive Skin Condition Only:
  • Subject scoring greater than 30 for Section 2 - Sensitive v/s Resistant skin in modified Dr Baumann's\* skin type questionnaire.
  • Subject with sensitive skin as confirmed by Lactic Acid Stinging Test.

You may not qualify if:

  • Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.
  • Medication which may affect skin response and/or past medical history.
  • Subject having history of diabetes
  • Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
  • Subject suffering from any active clinically significant skin diseases which may contraindicate.
  • Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.
  • Participation in any patch test for irritation or sensitization within the last four weeks.
  • Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).
  • Use of any:
  • Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.
  • Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted)
  • Topical drugs used at application site.
  • Subject with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous.
  • Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.
  • Subject with known allergy or sensitization to medical adhesives, bandages.
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Gene Expression

Intervention Hierarchy (Ancestors)

Genetic Phenomena

Study Officials

  • Dr. Nayan Patel

    NovoBliss Research Private Limited

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Maheshvari Patel

CONTACT

Sheetal Khandwala

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Primary Irritation Patch Test Study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2025

First Posted

August 7, 2025

Study Start

August 25, 2025

Primary Completion

September 1, 2025

Study Completion

September 1, 2025

Last Updated

August 8, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share